RxDoctor Payments Data

Himadri Dasgupta, MD

Cardiovascular Disease · Lexington, SCNPI 1265489512

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,635 of the $17,947 with a category attached, or 87.1%. Amgen accounts for 92.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $7,458 and has fallen 99.8% since, to $16 in 2024. Among cardiovascular disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,947in general payments, 2019–2025

Across 135 payments — averaging $132.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$17K
  • Pfizer$342
  • AstraZeneca$199
  • E.r. Squibb & Sons, L.L.C.$167
  • Johnson & Johnson$143
  • Novartis$110
  • plus $409 from 9 others

What the payments were for

  • Speaking & faculty fees$15,63587%
  • Travel & lodging$2341%
  • Food & beverage$1,99211%
  • Education$860%

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,947 in reported general payments places this provider in the 90th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$266,030
Medicare patients
832
Services billed
4,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban397$400,266
EntrestoSacubitril/Valsartan237$245,370
FarxigaDapagliflozin Propanediol142$133,804
JardianceEmpagliflozin129$121,966
XareltoRivaroxaban124$118,956
Repatha SureclickEvolocumab81$87,439
MultaqDronedarone Hcl38$42,433
VascepaIcosapent Ethyl25$14,304
BrilintaTicagrelor15$13,041
Metoprolol Succinate482$7,853
Icosapent Ethyl22$6,817
Rosuvastatin Calcium320$6,541
Ezetimibe245$5,301
Atorvastatin Calcium485$5,262
Losartan Potassium344$3,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$342$400,266397 claims
NovartisEntresto$110$245,370237 claims
AstraZenecaFarxiga, Brilinta$199$146,844157 claims
Johnson & JohnsonXarelto$143$118,956124 claims
Sanofi-aventis U.S. LLCMultaq$16$42,43338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →